Stryker Corporation (NYSE:SYK) Receives $430.33 Average Price Target from Analysts

Stryker Corporation (NYSE:SYK) has been given an average recommendation of “Moderate Buy” by the twenty-one research firms that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $430.3333.

A number of brokerages recently commented on SYK. Rothschild & Co Redburn began coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Truist Financial set a $415.00 price target on shares of Stryker and gave the company a “hold” rating in a research note on Monday, August 4th. Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Evercore ISI upped their price target on shares of Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Institutional Trading of Stryker

Institutional investors and hedge funds have recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Stryker during the 2nd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Stryker during the 2nd quarter worth approximately $28,000. Sachetta LLC lifted its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the period. Kilter Group LLC bought a new stake in shares of Stryker during the 2nd quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute bought a new stake in shares of Stryker during the 2nd quarter worth approximately $29,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 1.1%

Stryker stock opened at $370.59 on Tuesday. The firm has a market capitalization of $141.68 billion, a PE ratio of 49.08, a P/E/G ratio of 2.67 and a beta of 0.94. The company’s 50-day moving average is $382.81 and its 200-day moving average is $378.93. Stryker has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts anticipate that Stryker will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.